Abstract

BackgroundComplete avoidance of residual neuromuscular blockade (RNMB) during the postoperative period has not yet been achieved in current anesthesia practice. Evidently, compliance with NMB monitoring is persistently low, and the risk of RNMB during the perioperative period remains underestimated. To our knowledge, no publications have reported the incidence of RNMB in a university hospital where access to quantitative NMB monitoring and sugammadex is unlimited and where NMB management is not protocolised. The primary aim of this study was to estimate the incidence of RNMB in patients managed with or without sugammadex or neostigmine as antagonists and quantitative NMB monitoring in the operating room. The secondary aim was to explore the associations between RNMB and potentially related variables.MethodsThis retrospective observational cohort study was conducted at a tertiary referral university hospital in Buenos Aires, Argentina. Records created between June 2015 and December 2015 were reviewed. In total, 240 consecutive patients who had undergone elective surgical procedures requiring NMB were included. All patients were monitored via acceleromyography at the adductor pollicis muscle within 5 min of arrival in the postanaesthesia care unit (PACU). Scheduled recovery in the intensive care unit was the only exclusion criterion.ResultsRNMB was present in 1.6% patients who received intra-operative quantitative NMB monitoring and 32% patients whose NMB was not monitored (P < 0.01). Multivariable analysis revealed that the use of intra-operative quantitative NMB monitoring and sugammadex were associated with a lower incidence of RNMB, with calculated odds ratios of 0.04 (95% confidence interval [CI]: 0.005 to 0.401) and 0.18 (95% CI: 0.046 to 0.727), respectively.ConclusionsThe results of the present study suggest that intra-operative quantitative NMB monitoring and use of sugammadex are associated with a decreased incidence of RNMB in the PACU, reinforcing the contention that the optimal strategy for RNMB avoidance is the use of quantitative NMB monitoring and eventual use of reversal agents, if needed, prior to emergence from anaesthesia.

Highlights

  • Complete avoidance of residual neuromuscular blockade (RNMB) during the postoperative period has not yet been achieved in current anesthesia practice

  • Secondary aim To explore the associations between RNMB and potentially related variables such as the use of Neuromuscular blockade (NMB) monitoring, duration of surgery, type of Neuromuscular blocking drug (NMBD), type of reversal agent, and time between the last NMBD administration and Train-of-four ratio (TOFR) in the postanaesthesia care unit (PACU)

  • There were no significant differences pertaining to age, sex, body mass index, American Society of Anesthesiologists (ASA) physical status, or type of NMBD used in both groups

Read more

Summary

Introduction

Complete avoidance of residual neuromuscular blockade (RNMB) during the postoperative period has not yet been achieved in current anesthesia practice. The primary aim of this study was to estimate the incidence of RNMB in patients managed with or without sugammadex or neostigmine as antagonists and quantitative NMB monitoring in the operating room. Complete avoidance of residual neuromuscular blockade (RNMB) during the postoperative period has not yet been achieved. The reported incidence varies from 20 to 50% in the postanaesthesia care unit (PACU), depending on the TOFR threshold (0.7 or 0.9) used to define RNMB in each study, type of neuromuscular blocking drugs (NMBDs) used, and the use of objective or intra-operative quantitative monitoring of neuromuscular function [3]. Several reports suggest that clinical evaluation and qualitative neuromuscular monitoring approaches are not sensitive enough to detect the presence of RNMB [7,8,9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call